PubMed · 2004 · 16 citations · 0 references
Veterinary MedicineBiotechnologyOncologyImmunizationImmunotherapyVaccinologyCancer ImmunotherapyCancer VaccinesClinical Development Of VaccinesClinical Vaccine TrialsTherapeutic VaccinesVaccinationCancer Vaccine DesignCancer Vaccine DevelopmentEvaluationPhase Ii InvestigationPhase Iii Clinical TrialsPhase Iii Vaccine TrialsProtein-based Cancer VaccinesTumor Antigen Vaccines
CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer.